This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Medivation Management Discusses Q2 2012 Results - Earnings Call Transcript

Medivation (MDVN)

Q2 2012 Earnings Call

August 09, 2012 4:30 pm ET


Anne Bowdidge

David T. Hung - Chief Executive Officer, President and Executive Director

C. Patrick Machado - Chief Financial Officer, Principal Accounting Officer, Chief Business Officer and Secretary

Lynn Seely - Chief Medical Officer and Senior Vice President

Cheryl Cohen - Chief Commercial Officer


John Beshai

Kimberly Lee - ThinkEquity LLC, Research Division

Yaron Werber - Citigroup Inc, Research Division

Y. Katherine Xu - William Blair & Company L.L.C., Research Division

Geoffrey C. Porges - Sanford C. Bernstein & Co., LLC., Research Division

Lee Kalowski - Crédit Suisse AG, Research Division

Biren Amin - Jefferies & Company, Inc., Research Division

Raghuram Selvaraju - Aegis Capital Corporation, Research Division

Ling Wang - Summer Street Research Partners

Eric Schmidt - Cowen and Company, LLC, Research Division

Howard Liang - Leerink Swann LLC, Research Division



Good day, everyone, and welcome to Medivation's scheduled conference call. This call is being recorded. [Operator Instructions] I would now like to turn the call over to Anne Bowdidge, Senior Director of Investor Relations. Please go ahead.

Anne Bowdidge

Thank you for joining us. On the call today from Medivation are Dr. David Hung, President and CEO; Patrick Machado, Chief Business and Financial Officer; Dr. Lynn Seely, Chief Medical Officer; and Cheryl Cohen, Chief Commercial Officer. We issued a press release earlier today that you can find on our website at

Before we begin, I'd like to remind you that various remarks we make on this call contain forward-looking statements that are made under the Safe Harbor provisions of the securities laws, including statements regarding the potential future regulatory approval and commercialization of enzalutamide and the timing thereof; continued clinical development of enzalutamide; potential future clinical trial events or results; the therapeutic potential and safety profiles of our product candidates; our future opportunities and milestones; and financial guidance for the remainder of 2012, including projected revenue recognition, operating expenses, capital expenditures and receipt of development milestone payments.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs